Simbolo Michele, Mafficini Andrea, Sikora Katarzyna O, Fassan Matteo, Barbi Stefano, Corbo Vincenzo, Mastracci Luca, Rusev Borislav, Grillo Federica, Vicentini Caterina, Ferrara Roberto, Pilotto Sara, Davini Federico, Pelosi Giuseppe, Lawlor Rita T, Chilosi Marco, Tortora Giampaolo, Bria Emilio, Fontanini Gabriella, Volante Marco, Scarpa Aldo
ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Department of Diagnostics and Public Health, Section of Anatomical Pathology, University and Hospital Trust of Verona, Verona, Italy.
J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29.
Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNETs) comprising the four World Health Organization classification categories: 53 typical carcinoid (TCs), 35 atypical carcinoid (ACs), 27 large-cell neuroendocrine carcinomas, and 33 small-cell lung carcinomas. A discovery screen was conducted on 46 samples by the use of whole-exome sequencing and high-coverage targeted sequencing of 418 genes. Eighty-eight recurrently mutated genes from both the discovery screen and current literature were verified in the 46 cases of the discovery screen, and validated on additional 102 LNETs by targeted NGS; their prevalence was then evaluated on the whole series. Thirteen of these 88 genes were also evaluated for copy number alterations (CNAs). Carcinoids and carcinomas shared most of the altered genes but with different prevalence rates. When mutations and copy number changes were combined, MEN1 alterations were almost exclusive to carcinoids, whereas alterations of TP53 and RB1 cell cycle regulation genes and PI3K/AKT/mTOR pathway genes were significantly enriched in carcinomas. Conversely, mutations in chromatin-remodelling genes, including those encoding histone modifiers and members of SWI-SNF complexes, were found at similar rates in carcinoids (45.5%) and carcinomas (55.0%), suggesting a major role in LNET pathogenesis. One AC and one TC showed a hypermutated profile associated with a POLQ damaging mutation. There were fewer CNAs in carcinoids than in carcinomas; however ACs showed a hybrid pattern, whereby gains of TERT, SDHA, RICTOR, PIK3CA, MYCL and SRC were found at rates similar to those in carcinomas, whereas the MEN1 loss rate mirrored that of TCs. Multivariate survival analysis revealed RB1 mutation (p = 0.0005) and TERT copy gain (p = 0.016) as independent predictors of poorer prognosis. MEN1 mutation was associated with poor prognosis in AC (p = 0.0045), whereas KMT2D mutation correlated with longer survival in SCLC (p = 0.0022). In conclusion, molecular profiling may complement histology for better diagnostic definition and prognostic stratification of LNETs. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
下一代测序(NGS)应用于148例肺神经内分泌肿瘤(LNET),这些肿瘤包括世界卫生组织分类的四个类别:53例典型类癌(TC)、35例非典型类癌(AC)、27例大细胞神经内分泌癌和33例小细胞肺癌。通过全外显子测序和418个基因的高覆盖靶向测序对46个样本进行了发现性筛查。在发现性筛查的46例病例中验证了来自发现性筛查和当前文献的88个反复突变基因,并通过靶向NGS在另外102例LNET中进行了验证;然后在整个系列中评估它们的发生率。还对这88个基因中的13个进行了拷贝数改变(CNA)评估。类癌和癌共享大多数改变的基因,但发生率不同。当突变和拷贝数变化合并时,MEN1改变几乎仅见于类癌,而TP53和RB1细胞周期调节基因以及PI3K/AKT/mTOR信号通路基因的改变在癌中显著富集。相反,在类癌(45.5%)和癌(55.0%)中发现染色质重塑基因的突变率相似,包括编码组蛋白修饰剂和SWI-SNF复合物成员的基因,这表明其在LNET发病机制中起主要作用。1例AC和1例TC显示与POLQ有害突变相关的高突变特征。类癌中的CNA比癌少;然而,AC显示出一种混合模式,即TERT、SDHA、RICTOR、PIK3CA、MYCL和SRC的增益发生率与癌相似,而MEN1缺失率与TC相似。多变量生存分析显示RB1突变(p = 0.0005)和TERT拷贝数增加(p = 0.016)是预后较差的独立预测因素。MEN1突变与AC的预后不良相关(p = 0.0045),而KMT2D突变与SCLC的较长生存期相关(p = 0.0022)。总之,分子谱分析可补充组织学检查,以更好地对LNET进行诊断定义和预后分层。© 2016作者。《病理学杂志》由约翰·威利父子有限公司代表大不列颠及爱尔兰病理学会出版。